Cite
HARVARD Citation
Schindler, T. et al. (n.d.). AB0423 Nobility, A Phase 2 Trial To Assess The Safety and Efficacy of Obinutuzumab, A Novel Type 2 Anti-CD20 Monoclonal Antibody (MAB), in Patients (PTS) with ISN/RPS Class III or IV Lupus Nephritis (LN). Annals of the rheumatic diseases. p. 1051. [Online].